|
|
|
40
|
A1032
|
APO-LABETALOL 200MG TAB (APO/COL)
|
LABETALOL
|
APO-LABETALOL
|
100'S
|
A
|
70.68
|
0.71
|
TABLET
|
120
|
TAB
|
APO
|
APOTEX INC.
|
COL
|
COLLINS LTD
|
B
|
2424
|
BETA ADRENERGIC BLOCKING AGENTS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
CARDIOVASCULAR DRUGS
|
|
|
|
|
42
|
A1032
|
APO-LABETALOL 200MG TAB (APO)
|
LABETALOL
|
APO-LABETALOL
|
100'S
|
A
|
72.09
|
0.72
|
TAB
|
120
|
BOTT
|
APO
|
APOTEX INC.
|
COL
|
AVENTA BARBADOS
|
B
|
2424
|
BETA ADRENERGIC BLOCKING AGENTS
|
2026-04-01
|
2028-03-31
|
|
ORAL
|
6
|
BETA ADRENERGIC BLOCKING AGENTS
|
|
|
|
|
41
|
A103B
|
APO-LABETALOL 200MG TAB (APO)
|
LABETALOL
|
APO-LABETALOL
|
100'S
|
A
|
72.09
|
0.7209
|
TAB
|
120
|
BOTT
|
APO
|
APOTEX INC.
|
ATB
|
ANSA TRADING BARBADOS LTD
|
B
|
2424
|
BETA ADRENERGIC BLOCKING AGENTS
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
6
|
BETA ADRENERGIC BLOCKING AGENTS
|
|
|
|
|
40
|
A151A
|
ADENOSINE 3MG/ML INJ (KWA/ATB)
|
ADENOSINE
|
ADENOSINE
|
10X2ML
|
BQ
|
47.57
|
4.76
|
INJECTION
|
0
|
VIAL
|
KWA
|
KWALITY PHARMACEUTICALS
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
240404
|
ANTIARRHYTHMIC AGENTS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
CARDIOVASCULAR DRUGS
|
|
|
|
|
41
|
A151F
|
ADENOSINE 3MG/ML INJ (LDP) (BQ)
|
ADENOSINE
|
ADENOSINE
|
10X2ML
|
BQ
|
51.38
|
5.1376
|
VIAL
|
30
|
BOX
|
LDP
|
LABDHI PHARMA
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
240404
|
ANTIARRHYTHMIC AGENTS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
ANTIARRHYTHMIC AGENTS
|
|
|
|
|
40
|
A151H
|
ADENOSINE 3MG/ML INJ (MON/PHA)
|
ADENOSINE
|
ADENOSINE
|
10X2ML
|
BQ
|
52.14
|
5.21
|
INJECTION
|
0
|
AMP
|
MON
|
MONTAGE PHARMACEUTICALS
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
240404
|
ANTIARRHYTHMIC AGENTS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
CARDIOVASCULAR DRUGS
|
|
|
|
|
42
|
A151H
|
ADENOSINE 3MG/ML INJ (MON)
|
ADENOSINE
|
ADENOSINE
|
10X2ML
|
BQ
|
17.83
|
1.78
|
AMPG
|
30
|
BOX
|
MON
|
MONTAGE PHARMACEUTICALS
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
240404
|
ANTIARRHYTHMIC AGENTS
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
ANTIARRHYTHMIC AGENTS
|
|
|
|
|
42
|
A151N
|
CARDIUREX 3MG/ML INJ (JLP) ADENOSINE
|
ADENOSINE
|
CARDIUREX
|
30X2ML
|
BQ
|
57.63
|
1.92
|
AMPG
|
30
|
AMP
|
JLP
|
JOHN LEE PHARMACEUTICALS
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
240404
|
ANTIARRHYTHMIC AGENTS
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
ANTIARRHYTHMIC AGENTS
|
|
|
|
|
40
|
A1813
|
ELECTROLYTES SOLN (BAX/STO)
|
ELECTROLYTES
|
ELECTROLYTES
|
1 LITRE
|
BQ
|
13.86
|
13.86
|
SOLUTION
|
0
|
BOTT
|
BAX
|
BAXTER EXPORT CORP.
|
STO
|
BRYDEN STOKES LTD
|
|
4012
|
REPLACEMENT THERAPY
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ELECTROLYTIC, CALORIC, AND WATER BALANCE
|
|
|
|
|
41
|
A1813
|
ELECTROLYTES SOLN (BAX)
|
ELECTROLYTES
|
ELECTROLYTES
|
1 LITRE
|
BQ
|
16.26
|
16.2556
|
BOTT
|
50
|
BOTT
|
BAX
|
BAXTER EXPORT CORP.
|
STO
|
BRYDEN STOKES LTD
|
|
4012
|
REPLACEMENT THERAPY
|
2024-04-01
|
2026-03-31
|
|
IV
|
6
|
REPLACEMENT THERAPY
|
|
|
|
|
42
|
A1813
|
ELECTROLYTES SOLN (BAX)
|
ELECTROLYTES
|
CARDIOPLEGIC
|
1 LITRE
|
BQ
|
5.06
|
5.06
|
BOTT
|
50
|
BOTT
|
BAX
|
BAXTER EXPORT CORP.
|
STO
|
BRYDEN STOKES LTD
|
|
4012
|
REPLACEMENT THERAPY
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
REPLACEMENT THERAPY
|
|
|
|
|
40
|
A1916
|
ALPROSTADIL 500MCG/ML INJ (SLS/AHI)
|
ALPROSTADIL
|
ALPROSTADIL
|
1ML AMP
|
BQ
|
399.59
|
399.59
|
INJECTION
|
0
|
AMP
|
SLS
|
SAMARTH LIFE SCIENCES
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
241292
|
VASODILATING AGENTS, MISCELLANEOUS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
CARDIOVASCULAR DRUGS
|
|
|
|
|
42
|
A1916
|
ALPROSTADIL 500MCG/ML INJ (SLS)
|
ALPROSTADIL
|
ALPROSTADIL
|
1ML AMP
|
BQ
|
398.07
|
398.07
|
AMPG
|
7
|
AMP
|
SLS
|
SAMARTH LIFE SCIENCES
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
241292
|
VASODILATING AGENTS, MISCELLANEOUS
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
VASODILATING AGENTS, MISCELLANEOUS
|
|
|
|
|
40
|
A1917
|
BIOGLANDIN 500MCG/ML INJ (UBI/RXP) ALPROSTADI
|
ALPROSTADIL
|
BIOGLANDIN
|
1ML AMP
|
BQ
|
237.85
|
237.85
|
INJECTION
|
0
|
AMP
|
UBI
|
UNITED BIOTECH (P) LIMITED
|
RXP
|
RX PRO INC
|
|
241292
|
VASODILATING AGENTS, MISCELLANEOUS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
CARDIOVASCULAR DRUGS
|
|
|
|
|
41
|
A1919
|
ALPROSTADIL 500MCG/ML INJ (KWA)
|
ALPROSTADIL
|
ALPROSTADIL
|
1ML AMP
|
BQ
|
485.2208
|
485.2208
|
AMP
|
7
|
AMP
|
KWA
|
KWALITY PHARMACEUTICALS
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
241292
|
VASODILATING AGENTS, MISCELLANEOUS
|
2024-04-01
|
2026-03-31
|
|
IV
|
6
|
VASODILATING AGENTS, MISCELLANEOUS
|
|
|
|
|
40
|
A2313
|
NEURONTIN 300MG CAP (PFI/STO) GABAPENTIN
|
GABAPENTIN
|
NEURONTIN
|
100'S
|
C
|
150.08
|
1.50
|
CAPSULE
|
0
|
CAP
|
PFI
|
PFIZER CORPORATION
|
STO
|
BRYDEN STOKES LTD
|
B
|
281292
|
ANTICONVULSANTS MISCELLANEOUS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
0
|
CENTRAL NERVOUS SYSTEM DRUGS
|
|
|
|
|
41
|
A2313
|
NEURONTIN 300MG CAP (PFI) GABAPENTIN (C)
|
GABAPENTIN
|
NEURONTIN
|
100'S
|
C
|
151.44
|
1.5144
|
CAP
|
180
|
BOX
|
PFI
|
PFIZER CORPORATION
|
STO
|
BRYDEN STOKES LTD
|
B
|
281292
|
ANTICONVULSANTS MISCELLANEOUS
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
6
|
ANTICONVULSANTS MISCELLANEOUS
|
|
|
|
|
40
|
A2314
|
APO-GABAPENTIN 300MG CAP (APO/COL)
|
GABAPENTIN
|
APO-GABAPENTIN
|
100'S
|
A
|
11.77
|
0.12
|
CAPSULE
|
180
|
CAP
|
APO
|
APOTEX INC.
|
COL
|
COLLINS LTD
|
B
|
281292
|
ANTICONVULSANTS MISCELLANEOUS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
CENTRAL NERVOUS SYSTEM DRUGS
|
|
|
|
|
42
|
A2314
|
APO-GABAPENTIN 300MG CAP (APO)
|
GABAPENTIN
|
APO-GABAPENTIN
|
100'S
|
C
|
13.21
|
0.13
|
CAP
|
180
|
BOTT
|
APO
|
APOTEX INC.
|
COL
|
AVENTA BARBADOS
|
B
|
281292
|
ANTICONVULSANTS MISCELLANEOUS
|
2026-04-01
|
2028-03-31
|
|
ORAL
|
6
|
ANTICONVULSANTS MISCELLANEOUS
|
|
|
|
|
42
|
A231AE
|
GABAPENTIN 300MG CAP (FSB)
|
GABAPENTIN
|
GABAPENTIN
|
100'S
|
A
|
7.04
|
0.07
|
CAP
|
180
|
|
FSB
|
FLAGSHIP BIOTECH
|
STO
|
BRYDEN STOKES LTD
|
B
|
281292
|
ANTICONVULSANTS MISCELLANEOUS
|
2026-04-01
|
2028-03-31
|
|
ORAL
|
6
|
ANTICONVULSANTS MISCELLANEOUS
|
2026-03-05
|
